Vis enkel innførsel

dc.contributor.authorBrekke, Kurt Richard
dc.contributor.authorHolmås, Tor Helge
dc.contributor.authorStraume, Odd Rune
dc.date.accessioned2008-08-27T13:45:25Z
dc.date.available2008-08-27T13:45:25Z
dc.date.issued2007-12
dc.identifier.issn0804-6824
dc.identifier.urihttp://hdl.handle.net/11250/163126
dc.description.abstractWe study the impact of regulatory regimes on generic competition and pharmaceutical pricing using a unique policy experiment in Norway, where reference pricing (RP) replaced price cap regulation in 2003 for a sub-sample of off-patent products. We exploit a detailed panel dataset at product level covering a wide set of off-patent drugs before and after the policy reform. Off-patent drugs not subject to reference pricing serve as our control group. We find that RP leads to lower relative prices, with the effect being driven by strong brand-name price reductions, and not increases in generic prices. We also find that RP increases generic competition, resulting in lower brand-name market shares. Finally, we show that RP has a strong negative effect on average prices at molecule level, suggesting significant cost-savings.en
dc.language.isoengen
dc.publisherNorwegian School of Economics and Business Administration. Department of Economicsen
dc.relation.ispartofseriesDiscussion paperen
dc.relation.ispartofseries2007:39en
dc.subjectpharmaceuticalsen
dc.subjectregulationen
dc.subjectgeneric competitionen
dc.titleRegulation, generic competition and pharmaceutical prices : theory and evidence from a natural experimenten
dc.typeWorking paperen
dc.subject.nsiVDP::Samfunnsvitenskap: 200::Økonomi: 210::Samfunnsøkonomi: 212en


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel